Table 1.

Outcomes by Treatment Group and Illness Duration at the Time of Treatment Initiation

	Placebo	Drug	P Value
Late treatment (48–119 hours)
Time from treatment initiation to symptom resolution, median days (95% CI)	4 (3.5, 5)	4 (3.5, 5)	.5
Probability of symptom resolution on day 3–4 of treatment (95% CI)	0.32 (0.17, 0.46)	0.37 (0.27, 0.47)	.5
Probability of symptom resolution on day 7 of treatment (95% CI)	0.86 (0.74, 0.97)	0.81 (0.73, 0.89)	.6
Probability of positive RT-PCR on day 3–4 of treatment (95% CI)	0.11 (0.01, 0.21)	0.13 (0.06, 0.20)	.8
Mean severity score*, median (IQR)	5.7 (2.5, 4.8)	6.1 (4.9, 7.7)	.5
Maximum severity score*, median (IQR)	11.5 (8, 14)	12 (9, 15)	.2
Early and late treatment (<120 hours)
Time from treatment initiation to symptom resolution, median days (95% CI)	4 (3.5, 4.5)	4 (3.5, 5)	.4
Probability of symptom resolution on day 3–4 of treatment (95% CI)	0.35 (0.21, 0.48)	0.39 (0.30, 0.48)	.6
Probability of symptom resolution on day 7 of treatment (95% CI)	0.89 (0.80, 0.98)	0.82 (0.75, 0.89)	.2
Probability of positive RT-PCR on day 3–4 of treatment (95% CI)	0.15 (0.05, 0.25)	0.18 (0.10, 0.25)	.6
Mean severity score*, median (IQR)	5.8 (4.8, 7.7)	6.1 (5.0, 7.7)	.6
Maximum severity score*, median (IQR)	11.5 (7.5, 14)	12 (10, 15)	.2

Abbreviations: CI, confidence interval; IQR, interquartile range; RT-PCR, reverse-transcription polymerase chain reaction.

*Patients aged ≥24 month, highest possible severity score was 24.